Peptide questions · Cagrilintide

Cagrilintide side effects: what studies and users report

Reviewed Evidence: EstablishedPublished by PepVault

The side effects most commonly reported for cagrilintide are nausea, constipation and diarrhea, among 4 the library lists; the library’s evidence on it includes controlled trials in people.

Its safety note opens: cagrilintide has no label of its own.

What is commonly reported with cagrilintide

  • Nausea
  • Constipation
  • Diarrhea
  • Injection-site reactions

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other metabolic & GLP-1 compounds the library lists it for
EffectAlso listed for (of 24)
Nausea21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more
Constipation13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more
Diarrhea20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more
Injection-site reactionsNone: listed for Cagrilintide alone
A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Track cagrilintide in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which cagrilintide side effects the metabolic & GLP-1 group shares

Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Cagrilintide shares 3 of its 4 listed effects with at least one other metabolic & GLP-1 compound; injection-site reactions is listed for cagrilintide alone.

What the cagrilintide safety notes say

The library’s safety note

Cagrilintide has no label of its own. In its 26-week phase 2 trial, GI side effects (mainly nausea, constipation and diarrhea) affected 41–63% across doses vs 32% on placebo, and injection-site reactions were among the most frequent events; they were mostly mild to moderate. A thorough QT study up to 4.5 mg found no clinically relevant effect on heart rhythm (QTc). It is an amylin analogue, not a GLP-1, but it is almost always run beside one, so that drug's own label warnings (including the rodent thyroid C-cell boxed warning and pancreatitis) apply to the stack, and the GI effects add up. These are trial findings; review them with your clinician.

The library’s interaction note

Its only published interaction data are with semaglutide: in phase 1b, cagrilintide did not change semaglutide's exposure or elimination. Amylin slows stomach emptying, which could change how quickly oral medicines are absorbed. Beside a GLP-1 the GI effects add up: in REDEFINE 1, 79.6% on the cagrilintide-semaglutide pair had GI side effects vs 39.9% on placebo. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the cagrilintide reports come from

The library rates the evidence on cagrilintide as established: clinical trials or FDA-approved use exist.

Of the library’s 8 research notes on cagrilintide, 7 rest on randomized trials and 1 on animal studies.

Our 7 study pages on cagrilintide: 7 randomized trials.

So cagrilintide has controlled trials in people to set its listed effects against.

What our cagrilintide study pages report on safety

Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1

Randomized trial, human, 2025: Stomach and gut side effects, including nausea, vomiting, diarrhea, constipation or belly pain, affected 79.6% on the combination and 39.9% on placebo, and most were short-lived and mild to moderate. In a large 68-week trial, pairing cagrilintide with semaglutide led to 20.4% average weight loss versus 3.0% on placebo, with gut side effects common but mostly mild to moderate.

Cagrilintide with semaglutide: 15.6% weight loss in type 2 diabetes

Randomized trial, human, 2023: Side effects were reported by 68%, 71% and 80% of each group, mostly mild or moderate stomach and gut effects, with no level 2 or 3 hypoglycemia (low blood sugar) and no deaths.

Cagrilintide with semaglutide: 17.1% weight loss at 2.4 mg, week 20

Randomized trial, human, 2021: Side effects were common in both groups: 69 of 71 people (97%) on cagrilintide and 23 of 24 (96%) on placebo had at least one, mostly mild to moderate, and 207 (37%) of the 566 events were gut-related. In this early 20-week trial, adding cagrilintide to semaglutide 2.4 mg brought more weight loss than semaglutide with placebo, and the share of people with side effects was similar between groups.

Questions people ask

What are the side effects of cagrilintide?

The side effects most commonly reported for cagrilintide are nausea, constipation and diarrhea, among 4 the library lists; the library’s evidence on it includes controlled trials in people.

Do cagrilintide’s side effects come from human studies?

The library rates the evidence on cagrilintide as established, and the library’s evidence on it includes controlled trials in people.

Which cagrilintide side effects are its own?

Among the metabolic & GLP-1 compounds, the library lists injection-site reactions for cagrilintide alone.

Does cagrilintide interact with other medicines?

The library’s interaction note on cagrilintide begins: Its only published interaction data are with semaglutide: in phase 1b, cagrilintide did not change semaglutide's exposure or elimination.

More on cagrilintide

Track it in the app

PepVault for iPhone

Track cagrilintide in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo